-
Endocrine Therapy versus Chemotherapy After CDK4/6 Inhibitor Progression in HR+/HER2- Metastatic Breast Cancer: A Multicenter Real-World Study from Turkey
14 Jan 2026 10:17 GMT
… Approximately 70% of metastatic breast cancers express hormone receptors … HER2-negative advanced breast cancer.19
Following progression … +/HER2- breast cancer. NPJ Breast Cancer. 2023;9(1 … everolimus plus exemestane after CDKi. Clin Breast Cancer. 2022;22 …
-
<![CDATA[FDA OKs Study Progression of (Z)-Endoxifen in Metastatic Breast Cancer ]]>
06 Jan 2026 23:54 GMT
… combination of the drug exemestane (Aromasin) and OFS. … with bilateral invasive breast cancer, inflammatory breast cancer, and/ … application for metastatic breast cancer. News release. Atossa … ER+/HER2- breast cancer (EVANGELINE). ClinicalTrials.gov. …
-
<![CDATA[Palazestrant Monotherapy Moves Into Phase 3 Examination in ER+, HER2– Breast Cancer]]>
25 Dec 2025 17:44 GMT
… IN ER+, HER2– BREAST CANCER
Palazestrant monotherapy was previously … locally advanced or metastatic breast cancer with measurable disease … once daily, and oral exemestane at 25 mg once … metastatic breast cancer: phase 1/2 study results. Breast Cancer Res. …
-
Management Strategies and Outcomes in HR+/HER2− Metastatic Breast Cancer Receiving CDK4/6 Inhibitors and Subsequent Therapies
23 Dec 2025 18:34 GMT
… combination with fulvestrant or exemestane, and talazoparib, achieved … and phenotypic evolution. Breast cancers can alter their receptor … therapy for advanced breast cancer. NPJ Breast Cancer. 2019;5:5 … HR+/HER2- breast cancer. Clin Breast Cancer. 2020;20(1 …
-
<![CDATA[1L Giredestrant Yields Improved IDFS vs ET in ER+/HER2– Breast Cancer]]>
18 Dec 2025 20:29 GMT
… with tamoxifen, anastrozole, letrozole, or exemestane.
The primary end point of … IDFS excluding second primary non-breast cancer. Secondary end points included … III lidERA Breast Cancer trial. Presented at: 2025 San Antonio Breast Cancer Symposium; December …
-
BioVaxys Announces Positive Phase 1 Clinical Study Results with Maveropepimut-S in Women with Hormone Receptor Positive/HER2 Negative Stage II-III Breast Cancer
18 Dec 2025 00:57 GMT
… breast cancer.
The global market for HER2-negative breast cancer … breast cancer patients that are resistant to breast cancer … , anastrozole, and exemestane for postmenopausal women … treatment of postmenopausal breast cancer with anastrozole, tamoxifen …
-
<![CDATA[Imlunestrant Combo Will Not Be Pursued for FDA Approval in Breast Cancer]]>
17 Dec 2025 21:27 GMT
… ’s choice of endocrine therapy: exemestane or fulvestrant). Patients were given … or without abemaciclib in advanced breast cancer (ABC): Updated efficacy results from … therapy in participants with early breast cancer (EMBER-4). ClinicalTrials.gov. Updated …
-
<![CDATA[Imlunestrant With/Without Abemaciclib Maintains PFS, OS Benefit in ER+/HER2– Breast Cancer]]>
12 Dec 2025 23:12 GMT
… patients with ER+, HER2– advanced breast cancer previously treated with aromatase inhibitors … s choice of endocrine therapy: exemestane or fulvestrant). Imlunestrant was … participants with ER+, HER2– advanced breast cancer (EMBER-3). ClinicalTrials.gov. …
-
<![CDATA[Inluriyo/Verzenio Extends Treatment Benefit in ER+/HER2– Breast Cancer ]]>
12 Dec 2025 22:45 GMT
… (ER-positive), HER2-negative advanced breast cancer, Inluriyo (Imlunestrant), alone or … -positive, HER2-negative advanced breast cancer previously treated with aromatase inhibitors … s choice of endocrine therapy: exemestane or fulvestrant). Inluriyo was …
-
<![CDATA[Giredestrant/Everolimus Improves PFS Across Subgroups After CDK4/6i in ER+/HER2– Breast Cancer]]>
12 Dec 2025 21:41 GMT
… ER+, HER2-negative breast cancer have limited effective options … standard-of-care ET (exemestane, fulvestrant, or tamoxifen … receptor–positive advanced breast cancer,” Rugo concluded.
References … HER2-negative advanced breast cancer previously treated with …
About
© 1995-2026